PubMed Health⌕ Search

Biomedical subjects

I Baksaas

Publications and source records attributed to I Baksaas.

At least 19 recordsLinked to original sources
PubMed1995

Improvement of serum lipids and blood pressure during intervention with n-3 fatty acids was not associated with changes in insulin levels in subjects with combined hyperlipidaemia.

OBJECTIVES: To investigate the effect of an omega-3 fatty acid concentrate K85 on serum lipids, lipoproteins, insulin metabolism and blood pressure in subjects with combined hyperlipidaemia. DESIGN: After a run-in dietary period of 10 weeks, subjects were randomly allocated to receive either encapsulated K85 (n = 28) or corn oil (n = 29). The intervention was double-blind. SETTING: An outpatient centre in Stavanger, Norway. SUBJECTS: Fifty-seven of 141 individuals, who, after the run-in period continued to meet the inclusion criteria: serum triglycerides of > or = 2.0 mmol L-1 and total serum cholesterol of > or = 6.0 mmol L-1. INTERVENTION: Encapsulated K85, containing 85% eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA), or corn oil, both administered in a daily dose of 4 g for 12 weeks. MAIN OUTCOME MEASURES: Change in metabolic and haemodynamic parameters related to intervention. RESULTS: Serum EPA and DHA increased significantly in the K85 group during the treatment period. The body-mass index remained unchanged. A 28% reduction in serum triglycerides was noted in the K85 group from the first 4 weeks. Total serum cholesterol was significantly reduced with both regimens. Serum high-density lipoprotein cholesterol increased significantly during the first 8 weeks in the K85 group. Significant reductions in systolic and diastolic blood pressures were noted in subjects on K85. The treatment did not affect serum glucose, plasma insulin and proinsulin levels. Insulin:glucose and proinsulin:glucose ratios remained unchanged. CONCLUSIONS: The atherogenic risk profile was improved with K85 in subjects with combined hyperlipidaemia, but n-3 fatty acids supplementation did not affect glucose/insulin homeostasis.

Adult↗
PubMed1993

General background.

Explore the source record for details and available documents.

Adverse Drug Reaction Reporting Systems↗
PubMed1990

Superparamagnetic particles as gastrointestinal contrast agent in magnetic resonance imaging of lower abdomen.

Negative gastrointestinal contrast enhancement can be achieved by oral administration of superparamagnetic particles. Their feasibility for the MR imaging of the female pelvis and lower abdomen was evaluated in studies on 32 follow-up patients with treated gynaecologic cancer. All the applied doses (0.2-1.0 mg particles/ml given in a volume of 600-800 ml) of contrast medium decreased the intraluminal signal. However, there was unpredictable individual variation in segmental distribution, and in some cases only a limited contrast effect was obtained. Image distortion was detected when the applied particle concentration exceeded 0.5 mg/ml, especially of the sagittal sections.

Abdomen↗
PubMed1988

An estimation of the prevalence of diabetes mellitus in Norway. A prescription registration study.

A prevalence of 0.9% for drug-treated diabetes mellitus was calculated (male 0.8; female 1.0) for Norway, based upon a survey of 6777 prescriptions of antidiabetic drugs at 61.5% of Norwegian pharmacies during a four-week period in 1984. A male dominance was found below the age of 50 years, gradually shifting towards female dominance among the elderly. These findings are in accordance with a population screening on diabetes mellitus in the county of Nord-Trøndelag, and may indicate that prescription data can be a valuable source in the estimation of sex and age prevalence figures. Compared to screening, prescription studies are more simple to perform and cheaper, and can provide valuable background information in primary health care.

Administration, Oral↗
PubMed1986

Therapeutic traditions in Northern Ireland, Norway and Sweden: I. Diabetes. WHO Drug Utilization Research Group (DURG).

A questionnaire survey was carried out to explore differences in the approach to treatment of patients with Type II diabetes between physicians in Northern Ireland, Norway and Sweden, and to discover to what extent it could account for the three-fold difference in drug use between the countries. A representative sample of 400 physicians in each country was asked to give their opinions on the choice of therapy for three model cases designed to cover the spectrum of treatment - from diet alone to insulin. Significantly more Swedish (65%) than Northern Irish (51%) and Norwegian (52%) doctors suggested diet alone for uncomplicated diabetes recently discovered in a middle aged, overweight man. For symptomatic diabetes in a 76 year old over-weight woman with few retinal microaneurysms, the majority of physicians in all three countries suggested treatment with sulphonylureas. Biguanides were here a more common alternative in Northern Ireland than in Scandinavia. For suspected secondary treatment failure in a 63 year old woman with no signs of complications, insulin was suggested by 71% of the Norwegian doctors but only by 44 and 49% of those in Northern Ireland and Sweden, respectively. General practitioners tended to suggest oral treatment earlier and to maintain it longer than hospital physicians. The study has demonstrated significant differences in the approach to treatment of Type II diabetes mellitus between physicians in the three countries. However, the differences were more prominent in the choice of drugs than in the threshold of drug treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

Diabetes Mellitus↗
PubMed1986

Therapeutic traditions in Northern Ireland, Norway and Sweden: II. Hypertension. WHO Drug Utilization Research Group (DURG).

A questionnaire survey based on hypertension case histories was performed among a representative sample of 400 GP's and hospital doctors in Northern Ireland, Norway and Sweden, countries having markedly different utilization of antihypertensive drugs. We found a greater propensity to start antihypertensive drug treatment in Northern Ireland than in Norway and Sweden. This was true both in mild diastolic and isolated systolic hypertension. Yet the utilization of antihypertensive drugs in Sweden is about 60% higher than in Northern Ireland and 30% higher than in Norway. Swedish physicians preferred beta-blockers as their first choice to a greater extent than physicians in Northern Ireland and Norway who selected thiazides more often. In general, the choice of drugs agreed with the sales and prescribing patterns in the three countries. Besides providing more insight in therapeutic traditions the study indicates that the lower prescribing of antihypertensive drugs in Northern Ireland, and to some extent in Norway, compared to Sweden, might be due to differences in true or apparent morbidity.

Antihypertensive Agents↗
PubMed1985

Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden.

The amount of antihypertensive and antidiabetic drugs based of defined daily doses per 1000 inhabitants per day varies two to three fold between Northern Ireland, Norway, and Sweden. We explored whether variations based on the universally applied defined daily doses might be accounted for by national differences in the actual average prescribed daily doses. Use of prescribed daily doses for antihypertensive drugs resulted in Northern Irish and Norwegian consumption figures which were respectively 40 and 21% lower than the Swedish one, compared to 38 and 25% when defined daily doses were used. The effect of population age-sex differences on the gross defined daily doses per 1000 inhabitants per day figures was determined by applying the Northern Irish or Norwegian age-sex group proportions to Swedish age-sex specific sales data. Taking population differences into account would have resulted in antihypertensive drug use being 21 rather than 38% less in Northern Ireland and 18 rather than 25% less in Norway. Also adjustment for prescribed daily doses left an unexplained difference of 23% between Sweden and Northern Ireland and 14% between Sweden and Norway. For oral antidiabetics use of prescribed daily doses resulted in a Northern Irish - Swedish difference of 62% compared to 67% when defined daily doses were used. Simultaneous adjustment for population differences and prescribed to defined daily dose variations left a 52% difference.

Adolescent↗
PubMed1984

Patterns in drug utilization--national and international aspects: antihypertensive drugs.

There is a reasonable agreement between defined daily doses (DDDs) and prescribed daily doses (PDDs) of antihypertensive drugs, at least in Norway and Sweden. Sales and prescriptions of antihypertensive drugs in seven European countries (CSSR, Denmark, Finland, Iceland, Northern Ireland, Norway and Sweden) have increased 50 to 200% during the last 10 years. The drug statistics also illustrate marked qualitative and quantitative differences in the utilization of antihypertensive drugs between these seven European countries. Mortality in cardiovascular diseases also differs between these countries, particularly between Northern Ireland and Finland and the other countries. So do sales of alcohol and tobacco. However, none of these factors seem to co-vary with drug utilization.

Adrenergic beta-Antagonists↗
PubMed1980

Patient reaction to information and motivation factors in long-term treatment with antihypertensive drugs.

In order to learn more about the patient-physician relationship, various aspects of information and communication, patient desires and complaints, a questionnaire form was mailed to three groups of male hypertensive patients. Group A consisted of 264 patients, response rate 61% (160 patients), originating from the employees' health service at two factories in Norway, and groups B (drug-treated) and C (not drug-treated) comprised 441 patients, response rate 82% (362 patients), and 328 patients, response rate 81% (265 patients), respectively, from the hypertension trial of the Oslo Study. Information and/or communication failure was observed in all groups, more in group A than in groups B and C. More information was wanted by 50--75% of the patients, especially in written form. More than one half of the patients expressed complaints which might have been misinterpreted as being due to drug treatment. With the exception of asthenia/drowsiness, impotence and podagra, which occurred more frequently in group B than in group C, the pattern of complaints was similar in these two groups.

Adult↗